High-Density Lipoprotein (HDL) Particle Subpopulations in Heterozygous Cholesteryl Ester Transfer Protein (CETP) Deficiency: Maintenance of Antioxidative Activity

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Chantepie, Sandrine ^a,e   Bochem, Andrea E ^b   Chapman, M John ^a,c,d   Hovingh, G Kees ^b   Kontush, Anatol ^a,c,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTER TRANSFER PROTEIN DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY STUDY; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN CELL; INTRON; LIPID COMPOSITION; LIPID OXIDATION; MALE; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DEFICIENCY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIOXIDANTS; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HETEROZYGOTE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84870016751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049336     Document Type: Article

References (66)

1. Camont L, Chapman MJ, Kontush A, (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17: 594-603.
2. Kronenberg F, Coon H, Ellison RC, Borecki I, Arnett DK, et al. (2002) Segregation analysis of HDL cholesterol in the NHLBI Family Heart Study and in Utah pedigrees. Eur J Hum Genet 10: 367-374.
3. Perusse L, Rice T, Despres JP, Bergeron J, Province MA, et al. (1997) Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. Arterioscler Thromb Vasc Biol 17: 3263-3269.
4. Pietilainen KH, Soderlund S, Rissanen A, Nakanishi S, Jauhiainen M, et al. (2009) HDL subspecies in young adult twins: heritability and impact of overweight. Obesity (Silver Spring) 17: 1208-1214.
5. Weissglas-Volkov D, Pajukanta P, (2010) Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 51: 2032-2057.
6. Chapman MJ, Le Goff W, Guerin M, Kontush A, (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31: 149-164.
7. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A, (2003) Genetics of HDL regulation in humans. Curr Opin Lipidol 14: 273-279.
8. Plengpanich W, Siriwong S, Khovidhunkit W, (2009) Two novel mutations and functional analyses of the CETP and LIPC genes underlying severe hyperalphalipoproteinemia. Metabolism 58: 1178-1184.
9. Thompson JF, Wood LS, Pickering EH, DeChairo B, Hyde CL, (2007) High-density genotyping and functional SNP localization in the CETP gene. J Lipid Res 48: 434-443.
10. Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, et al. (2009) A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 205: 506-511.
11. Weissglas-Volkov D, Aguilar-Salinas CA, Sinsheimer JS, Riba L, Huertas-Vazquez A, et al. (2010) Investigation of Variants Identified in Caucasian Genome-Wide Association Studies for Plasma High-Density Lipoprotein Cholesterol and Triglycerides Levels in Mexican Dyslipidemic Study Samples. Circ Cardiovasc Genet 3: 31-38.
12. Klos KL, Kullo IJ, (2007) Genetic determinants of HDL: monogenic disorders and contributions to variation. Curr Opin Cardiol 22: 344-351.
13. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, et al. (2008) Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299: 2777-2788.
14. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, et al. (2008) CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 29: 2792-2799.
15. Wilson PW, (2008) CETP genes, metabolic effects, and coronary disease risk. JAMA 299: 2795-2796.
16. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, et al. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111: 278-287.
17. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, et al. (2004) A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45: 948-953.
18. Ridker PM, Pare G, Parker AN, Zee RYL, Miletich JP, et al. (2009) Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study. Circ Cardiovasc Genet 2: 26-33.
19. Anand SS, Xie C, Pare G, Montpetit A, Rangarajan S, et al. (2009) Genetic Variants Associated With Myocardial Infarction Risk Factors in Over 8000 Individuals From Five Ethnic Groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet 2: 16-25.
20. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A, (2000) Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101: 1907-1912.
21. Tall AR, (2009) The Effects of Cholesterol Ester Transfer Protein Inhibition on Cholesterol Efflux. Am J Cardiol 104: 39E-45E.
22. Plengpanich W, Le Goff W, Poolsuk S, Julia Z, Guerin M, et al. (2011) CETP deficiency due to a novel mutation in the CETP gene promoter and its effect on cholesterol efflux and selective uptake into hepatocytes. Atherosclerosis 216: 370-373.
23. Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, et al. (2009) Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 402: 19-24.
24. van der Steeg WA, Hovingh GK, Klerkx AHEM, Hutten BA, Nootenboom IC, et al. (2007) Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J Lipid Res 48: 674-682.
25. Rumsey SC, Stucchi AF, Nicolosi RJ, Ginsberg HN, Ramakrishnan R, et al. (1994) Human plasma LDL cryopreserved with sucrose maintains in vivo kinetics indistinguishable from freshly isolated human LDL in cynomolgus monkeys. J Lipid Res 35: 1592-1598.
26. Egloff M, Leglise D, Duvillard L, Steinmetz J, Boyer MJ, et al. (1999) [Multicenter evaluation on different analyzers of three methods for direct HDL-cholesterol assay]. Ann Biol Clin (Paris) 57: 561-572.
27. Friedewald WT, Levy RI, Fredrickson DS, (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
28. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A, (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24: 188-194.
29. Niemeijer-Kanters SD, Dallinga-Thie GM, de Ruijter-Heijstek FC, Algra A, Erkelens DW, et al. (2001) Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis 156: 209-216.
30. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM, (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22: 339-358.
31. Kontush A, Chantepie S, Chapman MJ, (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23: 1881-1888.
32. Mezzetti A, Cipollone F, Cuccurullo F, (2000) Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 47: 475-488.
33. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, et al. (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89: 4963-4971.
34. Kontush A, de Faria EC, Chantepie S, Chapman MJ, (2004) Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 24: 526-533.
35. Sattler W, Christison J, Stocker R, (1995) Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free RadicBiolMed 18: 421-429.
36. Christison JK, Rye KA, Stocker R, (1995) Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. JLipid Res 36: 2017-2026.
37. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, et al. (1998) Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. JBiolChem 273: 6080-6087.
38. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R, (1998) Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. JBiolChem 273: 6088-6095.
39. Zerrad-Saadi A, Therond P, Chantepie S, Couturier M, Rye K-A, et al. (2009) HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis. Arterioscler Thromb Vasc Biol 29: 2169-2175.
40. Kontush A, Chapman MJ, (2006) Functionally defective HDL: A new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 3: 342-374.
41. Kontush A, de Faria EC, Chantepie S, Chapman MJ, (2005) A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182: 277-285.
42. Kontush A, Chapman MJ, (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 21: 312-318.
43. Duriez P, (2007) CETP inhibition. The Lancet 370: 1882-1883.
44. Boekholdt SM, Thompson JF, (2003) Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 44: 1080-1093.
45. Tsai MY, Johnson C, Kao WHL, Sharrett AR, Arends VL, et al. (2008) Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 200: 359-367.
46. Rotllan N, Calpe-Berdiel L, Guillaumet-Adkins A, Suren-Castillo S, Blanco-Vaca F, et al. (2008) CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Atherosclerosis 196: 505-513.
47. Bisoendial RJ, Hovingh GK, El Harchaoui K, Levels JHM, Tsimikas S, et al. (2005) Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25: e133-134.
48. Sugano M, Sawada S, Tsuchida K, Makino N, Kamada M, (2000) Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 41: 126-133.
49. Gaut JP, Heinecke JW, (2001) Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med 11: 103-112.
50. Yoshida H, Kisugi R, (2010) Mechanisms of LDL oxidation. Clin Chim Acta 411: 1875-1882.
51. Tsimikas S, Miller YI, (2011) Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 17: 27-37.
52. Joy T, Hegele RA, (2008) Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 7: 143-155.
53. Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T, (1997) HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem 30: 221-225.
54. Huang JM, Huang ZX, Zhu W, (1998) Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Clin Biochem 31: 537-543.
55. Orloff DG, (2007) Regulatory considerations in the development of high-density lipoprotein therapies. Am J Cardiol 100: S10-14.
56. Cefalu AB, Noto D, Magnolo L, Pinotti E, Gomaraschi M, et al. (2009) Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. Atherosclerosis 204: 202-207.
57. Kolovou G, Stamatelatou M, Anagnostopoulou K, Kostakou P, Kolovou V, et al. (2010) Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome. Open Cardiovasc Med J 4: 14-19.
58. Koropatnick TA, Kimbell J, Chen R, Grove JS, Donlon TA, et al. (2008) A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-american men. J Gerontol A Biol Sci Med Sci 63: 1235-1240.
59. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, et al. (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23: 160-167.
60. Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, et al. (2005) Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 77: 2690-2702.
61. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, et al. (2010) Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib. Arterioscler Thromb Vasc Biol 30: 1430-1438.
62. Niesor EJ, Okamoto H, Maugeais C, von der Mark E, Brousse M, et al. (2009) Abstract 1271: The Effects of Dalcetrapib on Macrophage Reverse Cholesterol Transport in a Rodent Model. Circulation 120: S468-a-.
63. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, et al. (2010) Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 51: 3443-3454.
64. Kontush A, Chapman MJ (2012) High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics. New York: Wiley & Sons. 648 p.
65. Kontush A, Guerin M, Chapman MJ, (2008) Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 5: 329-336.
66. Masson D, Jiang X-C, Lagrost L, Tall AR, (2009) The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 50: S201-206.